MedPath
HSA Approval

DBL Irinotecan Injection Concentrate 20mg/ml

SIN13367P

DBL Irinotecan Injection Concentrate 20mg/ml

DBL Irinotecan Injection Concentrate 20mg/ml

October 26, 2007

PFIZER PRIVATE LIMITED

PFIZER PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPFIZER PRIVATE LIMITED
Licence HolderPFIZER PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION, CONCENTRATE

INTRAVENOUS

Medical Information

L01XX19

xl 01 xx 19

Manufacturer Information

PFIZER PRIVATE LIMITED

Zydus Hospira Oncology Private Limited

Active Ingredients

Irinotecan hydrochloride trihydrate

20mg/mL

Irinotecan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DBL Irinotecan Injection Concentrate 20mg/ml - HSA Approval | MedPath